Reports
As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.
Sale
Global Cancer/Tumour Profiling Market: By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Others; By Biomarker Type; By Technology; By Application; Regional Analysis; Historical Market and Forecast (2016-2026); Market Dynamics; Competitive Landscape; Industry Events and Developments
Global Cancer/Tumour Profiling Market Outlook
The global cancer/tumour profiling market attained a value of USD around 7.8 billion in 2020. The cancer/tumour profiling market is further expected to grow in the forecast period of 2021-2026 at a CAGR of 10.2% to reach USD 14 billion by 2026.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The rising rate of cancer globally and the growing use of biomarkers in the production of tumours are the main drivers for the growth of the cancer/tumour profiling market.
Properties and Applications
Cancer is a life-threatening illness that is characterised by uncontrolled cell growth. This is mainly due to environmental reasons which alter the gene encoding that regulates cells. The resulting cell mutation results in abnormal cell growth, killing the surrounding normal tissue and then spreading it to very important organs. Cancer/tumour profiling is done to gain insight into a patient's cancer profile and genomic adjustments that enable physicians to guide a patient to the most appropriate treatment. Therefore, profiling also allows doctors to avoid interventions that are questionable and, thus, reduce mistakes and trial procedures.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The types of cancer can be divided into:
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Melanoma
- Others
The types of biosensors can be segmented into:
- Genetic Biomarkers
- Protein Biomarkers
- Others
The cancer/tumour profiling market can be broadly categorised based on technology into:
- Immunoassays
- Next-Generation Sequencing
- Polymerase Chain Reaction
- In Situ Hybridization
- Microarrays
- Mass Spectrometry
- Others
It finds its uses in the research and clinical applications.
Research applications can be further divided into:
- Biomarker Discovery
- Personalized Medicine
Clinical applications are further categorised into:
- Diagnostics
- Prognostics
- Monitoring and Treatment
- Screening
The EMR report looks into the regional markets of cancer/tumour profiling like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Analysis
A significant growth in the global market for cancer/tumour profiling is expected in the coming years, mainly owing to the increased funding of activities to improve the overall course of the diagnosis and treatment of the disease and the recent comprehensive technological advancements in the area of tumour profiling. The market is also being driven by the growing use of medical diagnostics and the resulting increase in the demand for personalized medicinal products.
The constantly increasing socio-economic burden of cancer and the demand from the health industry to establish effective methods of treating and controlling it also drives the market for the profiling of cancer/tumours. Nonetheless, the additional expenditure needed by profiling procedures may in some way impede its adoption, limiting the scope of these processes to high-income regions. Nonetheless, through government intervention and support from the public and private institutions for cancer diagnosis and treatment are expected to allow the market to achieve promising avenues for development.
Competitive Landscape
The report presents a detailed analysis of the following key players in the global cancer/tumour profiling market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- Illumina, Inc. (NASDAQ: ILMN)
- Qiagen N.V.
- Neogenomic Laboratories, Inc.
- Sysmex Corporation
- HTG Molecular Diagnostics, Inc.
- Helomics Corporation
- Genomic Health, Inc.
- Caris Life Sciences
- Others
The EMR report gives an in-depth insight into the cancer/tumour profiling market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
Key Questions Answered in the Market Report
- How has the global cancer/tumour profiling market performed in the previous years (2016-2020)?
- What is the forecast assessment of the cancer/tumour profiling market for 2021-2026?
- What are the major drivers of the historical (2016-2020) and forecast (2021-2026) periods?
- What are the major constraints of the historical (2016-2020) and forecast (2021-2026) periods?
- What are the major demand indicators of the global cancer/tumour profiling market?
- Who are the key players in the global cancer/tumour profiling market?
- What is the degree of competition in the global cancer/tumour profiling market?
- What are the major events and developments taking place within the global cancer/tumour profiling industry?
*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.
1 Preface
1.1 Objectives of the Study
1.1.1 Research Objective
1.1.2 Key Findings of the Report
2 Research Methodology
2.1 Data Extraction
2.2 Data Corroboration
2.3 Market Structure
2.4 Assumptions
2.5 Market Models
3 Introduction
3.1 Market Outlook
3.2 Market Scope and Segmentation
3.3 Additional Insights
4 Executive Summary
4.1 Key Market Developments
4.2 Market Analysis
4.3 Key Players
4.4 Cost Structure
4.5 Market Revenue and Growth
5 Market Dynamics
5.1 Market Driver Analysis
5.2 Market Restraint Analysis
5.3 Industry Challenges
5.4 Industry Opportunities
6 Global Cancer/Tumour Profiling Market Analysis
6.1 Figure: Global Cancer/Tumour Profiling Historical Market (2016-2020) & Forecast (2021-2026)
6.2 Chart: Global Cancer/Tumour or Profiling Market Breakup by Cancer Type
6.2.1 Breast Cancer
6.2.2 Lung Cancer
6.2.3 Colorectal Cancer
6.2.4 Prostate Cancer
6.2.5 Melanoma
6.2.6 Others
6.3 Figure: Global Cancer/Tumour Profiling Market Breakup by Cancer Type: Historical Market (2016-2020) & Forecast (2021-2026)
6.3.1 Breast Cancer
6.3.2 Lung Cancer
6.3.3 Colorectal Cancer
6.3.4 Prostate Cancer
6.3.5 Melanoma
6.3.6 Others
6.4 Chart: Global Cancer/Tumour Profiling Market Breakup by Biomarker Type
6.4.1 Genetic Biomarkers
6.4.2 Protein Biomarkers
6.4.3 Others
6.5 Figure: Global Cancer/Tumour Profiling Market Breakup by Biomarker Type: Historical Market (2016-2020) & Forecast (2021-2026)
6.5.1 Genetic Biomarkers
6.5.2 Protein Biomarkers
6.5.3 Others
6.6 Chart: Global Cancer/Tumour Profiling Market Breakup by Technology
6.6.1 Immunoassays
6.6.2 Next-Generation Sequencing
6.6.3 Polymerase Chain Reaction
6.6.4 In Situ Hybridization
6.6.5 Microarrays
6.6.6 Mass Spectrometry
6.6.7 Others
6.7 Figure: Global Cancer/Tumour Profiling Market Breakup by Technology: Historical Market (2016-2020) & Forecast (2021-2026)
6.7.1 Immunoassays
6.7.2 Next-Generation Sequencing
6.7.3 Polymerase Chain Reaction
6.7.4 In Situ Hybridization
6.7.5 Microarrays
6.7.6 Mass Spectrometry
6.7.7 Others
6.8 Chart: Global Cancer/Tumour Profiling Market by Application
6.8.1 Research Applications
6.8.1.1 Biomarker Discovery
6.8.1.2 Personalized Medicine
6.8.2 Clinical Applications
6.8.2.1 Diagnostics
6.8.2.2 Prognostics
6.8.2.3 Monitoring and Treatment
6.8.2.4 Screening
6.9 Figure: Global Cancer/Tumour Profiling Market by Application: Historical Market (2016-2020) & Forecast (2021-2026)
6.9.1 Research Applications
6.9.1.1 Biomarker Discovery
6.9.1.2 Personalized Medicine
6.9.2 Clinical Applications
6.9.2.1 Diagnostics
6.9.2.2 Prognostics
6.9.2.3 Monitoring and Treatment
6.9.2.4 Screening
6.10 Chart: Global Cancer/Tumour Profiling Market Breakup by Region
6.10.1 North America
6.10.1.1 United States of America
6.10.1.2 Canada
6.10.2 Europe
6.10.2.1 United Kingdom
6.10.2.2 Germany
6.10.2.3 France
6.10.2.4 Italy
6.10.2.5 Others
6.10.3 Asia Pacific
6.10.3.1 China
6.10.3.2 India
6.10.3.3 Japan
6.10.3.4 ASEAN
6.10.3.5 Others
6.10.4 Latin America
6.10.4.1 Brazil
6.10.4.2 Argentina
6.10.4.3 Mexico
6.10.4.4 Others
6.10.5 Middle East & Africa
6.10.5.1 Saudi Arabia
6.10.5.2 United Arab Emirates
6.10.5.3 Nigeria
6.10.5.4 South Africa
6.10.5.5 Others
6.11 Figure: Global Cancer/Tumour Profiling Breakup by Region: Historical Market (2016-2020) & Forecast (2021-2026)
6.11.1 North America
6.11.1.1 United States of America
6.11.1.2 Canada
6.11.2 Europe
6.11.2.1 United Kingdom
6.11.2.2 Germany
6.11.2.3 France
6.11.2.4 Italy
6.11.2.5 Others
6.11.3 Asia Pacific
6.11.3.1 China
6.11.3.2 India
6.11.3.3 Japan
6.11.3.4 ASEAN
6.11.3.5 Others
6.11.4 Latin America
6.11.4.1 Brazil
6.11.4.2 Argentina
6.11.4.3 Mexico
6.11.4.4 Others
6.11.5 Middle East & Africa
6.11.5.1 Saudi Arabia
6.11.5.2 United Arab Emirates
6.11.5.3 Nigeria
6.11.5.4 South Africa
6.11.5.5 Others
7 SWOT Analysis
7.1 Overview
7.2 Strengths
7.3 Weaknesses
7.4 Opportunities
7.5 Threats
8 Porter’s Five Forces Analysis
8.1 Overview
8.2 Buyer’s Power
8.3 Supplier’s Power
8.4 New Entrants
8.5 Degree of Rivalry
8.6 Substitutes
9 EMR’s Key Indicators for Demand
10 Competitive Landscape & Supplier Analysis
10.1 Illumina, Inc. (NASDAQ: ILMN)
10.1.1 Company Overview
10.1.2 Financial Analysis
10.2 Qiagen N.V. (NYSE: QGEN)
10.2.1 Company Overview
10.2.2 Financial Analysis
10.3 Neogenomic Laboratories, Inc. (NASDAQ: NEO)
10.3.1 Company Overview
10.3.2 Financial Analysis
10.4 Sysmex Corporation (TYO: 6869)
10.4.1 Company Overview
10.4.2 Financial Analysis
10.5 HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
10.5.1 Company Overview
10.5.2 Financial Analysis
10.6 Helomics Corporation
10.6.1 Company Overview
10.6.2 Financial Analysis
10.7 Genomic Health, Inc.
10.7.1 Company Overview
10.7.2 Financial Analysis
10.8 Caris Life Sciences
10.8.1 Company Overview
10.8.2 Financial Analysis
10.9 Others
11 Industry Events and Developments
Purchase Options
Call us on
Purchase Full Report
Mini Report
$ 1999
$1499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$3199$2499-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateFive User License
$4199$3499-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$5199$4499-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?RIGHT PEOPLE
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
RIGHT METHODOLOGY
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
RIGHT PRICE
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
RIGHT SUPPORT
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar ReportsThe global cancer screening market is driven by the surging cancer rates around the globe. Aided by the growing technological advancements, the market is expected to witness a further growth in the fo...
The global testosterone test kits market is being driven by the rising healthcare infrastructure and growing endocrine testing market. Aided by the growing R&D activities, the endocrine testing market...
The global glycated haemoglobin testing market witnessed a healthy growth in the historical period of 2016-2020 aided by rising prevalence of diabetes. The market is expected to grow at a CAGR of 9% d...
The global lipase testing market is being driven by the growing patient pool and lipase market. Aided by the rising research activities, the lipase market is expected to witness a healthy growth in th...
The global wellness genomics market attained a value of USD 4 billion in 2020, driven by the rising awareness of healthcare. Aided by the changing lifestyles to a healthier one, the market is expected...
NEWSLETTER